French medtech startup Datexim, the creator of a medical image analysis software that uses artificial intelligence against cervical cancer, has closed its second round of funding. The fresh funds will be used to launch new products, and expand further across France and internationally.
Founded in 2011, Datexim specializes in cervical cancer screening, and its solutions are already used routinely by several laboratories. In short, its solutions are an aide for pathologists that work with gynecologists. CE certified, it increases the speed of screening, accuracy, reliability and effectiveness. It’s used as a web application, which it says makes reading virtual slides as easy as browsing an internet site; users only need an internet browser to use it, making it accessible indeed.
Datexim has already successfully launched its first commercial operations and has set itself the objective of disseminating its solution on a large scale in the short term in France, and then internationally. The fresh funds will be used for this purpose, as well as supporting its R&D and sales teams, to initiate a phase of sustainable growth.
Arnaud Renouf, the President of Datexim commented on the development: “We are proud to have successfully launched our operations with laboratories which were able to quickly measure the operational benefits linked to our offer: reliability, working comfort, rapid diagnosis. Thanks to this fundraising, we are going to take a new step by developing our commercial and R&D strategy. We will thus accentuate our competitive advantage in order to become the global benchmark in our market. “
In the future, the medtech startup plans to diversify its offer and develop solutions that support the diagnosis of other cancers and diseases.